Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir + lamivudine versus dolutegravir + tenofovir alafenamide/emtricitabine in treatment-naive adults with HIV-1
2019-000800-14Phase 4Active
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dolutegravir, lamivudine, tenofovir alafenamide and emtricitabine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoints: Mean changes in proviral HIV-DNA in PBMCs at 96 weeks and Mean changes in HIV-RNA in PBMCs at 96 weeks. Started Nov 2019; status: active.
02
Drugs
dolutegravirlamivudinetenofovir alafenamideemtricitabine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2019-000800-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000800-14.